Newsletter Tool

Featured Story

Illumina completes Grail acquisition, regulators be damned

By Conor Hale

Despite looming antitrust investigations on both sides of the Atlantic, Illumina has pushed forward with its $8 billion deal to acquire Grail, maker of a newly launched blood test to detect dozens of different cancers.

'Our worst nightmare realized:' Investors, WHO slam J&J for exporting COVID shots produced in Africa

By Noah Higgins-Dunn

Johnson & Johnson is receiving fierce criticism from a group of outspoken shareholders for exporting millions of COVID-19 vaccine doses from a facility in South Africa to Europe despite glaring access inequalities, contributing to a “vaccine apartheid."

Survey: Nurses largely on board with COVID-19 vaccines but want more info on boosters, long-term safety

By Dave Muoio

The nationwide poll of nearly 5,000 nurses found broad trust in the shots but less solidarity on the subject of mandatory workplace requirements. Many called for more information on vaccine boosters and long-term effectiveness.

Biden administration's push for COVID boosters raises concerns about the science and morality of the plan

By Kevin Dunleavy

The Biden administration's endorsement of COVID booster shots has sparked equity and scientific concerns. The WHO has questioned the morality of the move and medical experts wonder if it is premature.

AHA presses for meeting with federal agencies as scrutiny of hospital deals ramps up

By Robert King

The American Hospital Association wants to meet with leaders of federal agencies that are examining the impact of hospital mergers, as the group seeks to push back on scrutiny of such deals.

Stryker president lays out 2-year retirement plan after three decades with the company

By Andrea Park

After spending his entire 30-plus-year career at Stryker, Timothy Scannell will soon part ways with the medical device maker to (ahem) strike a new path—one leading straight to retirement.

Is NICE becoming nicer? England's cost-effectiveness watchdog lays out plans to speed access to new medicines

By Noah Higgins-Dunn

The National Institute for Health and Care Excellence, or NICE, rolled out its planned remodel on Thursday aimed at providing “faster, fairer” access to the drugs and devices it reviews for National Health Services patients.

CRISPR pioneer Feng Zhang's latest work delivers mRNA, gene therapy with a human protein

By Angus Liu

COVID-19 mRNA vaccines and existing gene therapies, including those built with the CRISPR-Cas9 gene-editing tool, are delivered into cells with viral vectors or lipid nanoparticles. A research team led by CRISPR pioneer Feng Zhang of the Broad Institute has developed a new mRNA delivery system that harnesses a human protein called PEG10.

KFF: Medicare Advantage payments increased federal spending by $7B in 2019

By Robert King

The federal government spent $7 billion more on Medicare Advantage plans than for traditional Medicare, according to a new analysis that arrives as the White House is exploring ways to cut spending.

COVID-19 tracker: Amgen mandates vaccines; Biden booster plan prompts scientific, morality concerns

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Amgen on Thursday became the latest drugmaker to say it'll require vaccines among its workforce. The Biden administration's plan to roll out boosters starting in September has raised concerns about the data supporting the move and the morality of the program. Plus more.

PM Tracker